YOLFTbeta
Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX · NASDAQ · Healthcare / Biotechnology

0.6917USD-0.02 (-3.12%)

Price History

Full chart

Market Stats

Previous Close0.714
Open0.714
Day Range0.69 – 0.7599
52-Week Range1.07 – 3.95
Volume119.31K
Market Cap43.07M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.49
Dividend Yield0.00%
Beta0.68
50-Day Avg1.19
200-Day Avg1.39

About

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jian Irish M.B.A., Ph.D.
  • Employees113
  • Headquarters5959 Horton Street, EmeryVille, CA, United States, 94608, USA
  • Websitehttps://metagenomi.co

Leadership

  • Dr. Jian Irish M.B.A., Ph.D.CEO, President & Director · b. 1964
  • Ms. Pamela M. Wapnick M.B.A.Chief Financial Officer · b. 1966
  • Mr. Matthew L. Wein J.D.Gen­er­al Coun­sel, Com­pli­ance Offi­cer, Head of BD&L and Cor­po­rate Secretary · b. 1971
  • Dr. Joseph Knowles M.D.Co-Founder & Member of Scientific Advisory Board
  • Mr. Mark LeonardSenior Vice Pres­i­dent of Tech­ni­cal Devel­op­ment & Oper­a­tions
  • Dr. Alan Brooks Ph.D.Senior Vice President of Research · b. 1966
  • Ms. Katalin Kauser M.D., Ph.D.Senior Vice Pres­i­dent of Trans­la­tion­al Biol­o­gy
  • Mr. Nikhil Bhide M.B.A.Senior Vice President of Business Development

Financials

Income Statement

Currency: USD2021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue243.00K17.20M44.76M52.30M25.21M
Growth (%)-+6978.19%+160.21%+16.84%-51.79%
Cost of Revenue387.00K1.73M94.40M5.41M5.32M
Gross Profit-144.00K15.47M-49.65M52.30M19.89M
Gross Margin-59.26%89.92%-110.93%100.00%78.91%
Operating Expense23.80M60.11M28.84M141.20M115.91M
Operating Income-23.95M-44.64M-78.49M-88.90M-96.01M
Operating Margin-9854.73%-259.53%-175.38%-170.00%-380.85%
EBITDA-20.75M-39.19M-56.02M-78.16M-82.61M
EBITDA Margin-8540.33%-227.87%-125.17%-149.47%-327.68%
Net Income-21.44M-43.59M-68.25M-78.06M-87.87M
Net Income Margin-8823.87%-253.45%-152.50%-149.26%-348.54%
R&D14.48M43.14M94.40M109.18M94.43M
R&D as % of Total Revenue5958.02%250.81%210.93%208.78%374.59%
Interest Expense302.00K98.00K0--
Interest Expense % of Total Revenue124.28%0.57%0.00%--

Balance Sheet

Currency: USD2021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets141.99M414.49M364.84M324.60M221.10M
Total Liabilities174.54M488.91M500.43M89.74M62.51M
Total Equity-32.54M-74.43M-135.58M234.86M158.60M
Cash39.30M184.44M140.60M27.39M41.72M
Total Debt48.93M18.57M48.23M45.78M40.66M
Net Debt9.63M-165.87M-92.37M18.39M-1.06M

Cash Flow

Currency: USD2021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow24.26M29.72M-91.41M-109.07M-88.89M
Investing Cash Flow-74.32M-122.20M45.73M-88.16M103.53M
Financing Cash Flow39.92M239.59M1.01M84.01M-356.00K
Capital Expenditure2.90M13.98M9.81M3.11M574.00K
Free Cash Flow21.35M15.75M-101.22M-112.19M-89.47M
FCF to OCF88.03%52.98%110.74%102.85%100.65%

Earnings

Report DateMar 27, 2024May 14, 2024Aug 14, 2024Nov 13, 2024Mar 17, 2025May 13, 2025Aug 13, 2025Nov 11, 2025Mar 6, 2026May 11, 2026Aug 10, 2026Nov 10, 2026
EPS Estimate-2.04-0.67-0.81-0.74-0.77-0.51-0.61-0.53-0.58-0.55-0.63-0.74
EPS Actual-0.51-2.08-0.29-0.51-0.37-0.68-0.54-0.55-0.60-0.61-0.73-
Surprise74.76%-210.45%64.20%31.08%51.95%-33.33%11.48%-3.77%-2.56%-10.91%-15.87%-
TimingPre-marketAfter-hoursPre-marketAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap43.07M
Enterprise Value-40.07M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.18
Price / Book0.38
EPS-2.49
Book Value2.98
Revenue (TTM)13.56M
Gross Profit (TTM)-75.03M
EBITDA-95.40M
Profit Margin0.00%
Operating Margin11195.72%
Return on Equity-60.61%
Return on Assets-28.19%
Shares Outstanding37.78M
Shares Float25.54M
Beta0.68
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 7.00
  • Strong Buy
    4
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
18.72%
Insiders
19.02%
Retail / Other
62.26%

Top Institutional Holders

  • Vanguard Capital Management, LLC
    1.06M2.80%
  • Renaissance Technologies Corp
    787.90K2.09%
  • Catalio Capital Management, LP
    528.99K1.40%
  • Peapod Lane Capital LLC
    525.02K1.39%
  • Two Sigma Investments LLC
    513.70K1.36%
  • Bridgeway Capital Management, LLC
    395.80K1.05%
  • Jacobs Levy Equity Management, Inc.
    382.15K1.01%
  • Geode Capital Management, LLC
    358.20K0.95%
  • PURA VIDA INVESTMENTS, LLC
    264.39K0.70%
  • BlackRock Inc
    230.13K0.61%
  • Wells Fargo & Co
    202.14K0.54%
  • Vanguard Fiduciary Trust Co
    170.17K0.45%
  • Jane Street Group LLC
    151.44K0.40%
  • State Street Corp
    120.43K0.32%
  • Millennium Management LLC
    114.03K0.30%
  • Resolute Advisors LLC
    89.94K0.24%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    741.41K1.96%
  • Bridgeway Ultra-Small Company
    327.10K0.87%
  • Fidelity Extended Market Index
    136.44K0.36%
  • iShares Micro-Cap ETF
    94.85K0.25%